Solventum Corporation (SOLV) Valuation
Historical valuation analysis based on 640 data points (2024-04-01 to 2026-10-16)
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since be...
Solventum Corporation (SOLV) currently trades at a P/E ratio of 10.19 (historical range: 7.22–51.05, median: 26.86), placing it at the 33th percentile — below its historical average, P/S ratio of 1.76 (range: 1.31–6.00, 60th percentile — above its historical average), EV/EBITDA of 32.80 (range: 6.89–50.94, 90th percentile).
Over the historical period (2024-04-01 to 2026-10-16), Solventum Corporation's P/E ratio has contracted by 59% over the observed period (from an average of 32.7 to 13.4).
Solventum Corporation trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 10.19 | 26.86 | 33th | below its historical average |
| P/S Ratio | 1.76 | 1.63 | 60th | above its historical average |
| EV/EBITDA | 32.80 | 24.87 | 90th | expensive relative to its history |
| FCF Yield | 0.45% | 3.14% | 25th | above its historical average |
Solventum Corporation (SOLV) Valuation & P/E History
Solventum Corporation (SOLV) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $85.81 with a market capitalization of $14.6 billion. This page provides historical valuation analysis for SOLV based on 640 data points covering 2024-04-01 to 2026-10-16. The P/E ratio of 10.19 is below the historical median of 26.86, placing SOLV at the 33th percentile of its valuation range. The P/S ratio of 1.76 compares to a median of 1.63.
SOLV Valuation Metrics & Historical Range
The valuation table above shows Solventum Corporation's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether SOLV is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests SOLV is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Solventum Corporation.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is SOLV Overvalued or Undervalued?
Solventum Corporation trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 61 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive SOLV is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full SOLV analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.SOLV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.